Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone marrow biopsy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    887 result(s) found for: Bone marrow biopsy. Displaying page 1 of 45.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2012-004285-18 Sponsor Protocol Number: 00002 Start Date*: 2012-11-08
    Sponsor Name:Helsingin yliopisto
    Full Title: The pain relieving effect of nitrous oxide during bone marrow aspiration and biopsy - a placebo-controlled and randomized trial
    Medical condition: This study is performed on adult patients with suspected or known hematologic disease undergoing bone marrow aspiration and biopsy. Study investigates inhaled mixture of nitrous oxide and oxygen in...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2010-021811-17 Sponsor Protocol Number: 00001 Start Date*: 2010-10-18
    Sponsor Name:Helsingin yliopisto [...]
    1. Helsingin yliopisto
    2. Helsingin yliopisto
    Full Title: Suun limakalvolle annosteltu fentanyyli luuydinaspiraatioon ja -biopsiaan liittyvän kivun hoidossa
    Medical condition: This study is performed on adult patients with suspected or known hematologic disease undergoing bone marrow aspiration and biopsy. Study investigates oral transmucosal fentanyl in the treatment of...
    Disease:
    Population Age: Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-005410-21 Sponsor Protocol Number: RAE03 Start Date*: 2006-04-20
    Sponsor Name:Bradford Teaching Hospitals NHS Foundation Trust
    Full Title: Improving the Patient's Experience of a Bone Marrow Biopsy - An evidence based approach to service improvement.
    Medical condition: Procedural pain experienced during bone marrow biopsy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002782-37 Sponsor Protocol Number: ENT05 Start Date*: 2005-11-17
    Sponsor Name:Heart of England NHS Foundation Trust
    Full Title: A Randomised Trial of Inhaled Entonox Plus Local Anaesthesia Versus Intravenous Midazolam Plus Local Anaesthesia To Improve Pain Control During Bone Marrow Biopsy
    Medical condition: This study will involve a group of patients requiring diagnostic bone marrow aspiration and biopsy. The reasons for these will include haematological abnormalities of the blood count , which may be...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002483-31 Sponsor Protocol Number: UZBRU_VHH2_2 Start Date*: 2020-11-30
    Sponsor Name:UZ Brussel
    Full Title: Phase II study to evaluate the clinical potential of 68GaNOTA-Anti-MMR-VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in oncological lesions, ...
    Medical condition: C1: malignancies of the head and neck. C2: malignancy with a solid component C3: carotid plaque, planned for (SOC) carotid endarterectomy. C4: biopsy-proven Hodgkin or non-Hodgkin lymphoma. C5: su...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001718-80 Sponsor Protocol Number: PRM-151G-101 Start Date*: 2016-02-18
    Sponsor Name:Promedior, Inc
    Full Title: A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)
    Medical condition: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-019248-37 Sponsor Protocol Number: IILINFL09 Start Date*: 2010-12-30
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular Non-Hodgkin’s Lymphoma
    Medical condition: Patients with advanced untreated Indolent non Follicular non-Hodgkin Lymphomas
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004347-10 Sponsor Protocol Number: 20080009 Start Date*: 2009-06-17
    Sponsor Name:Amgen Inc
    Full Title: A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated with Im...
    Medical condition: Thrombocytopenia associated with ITP
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) DE (Completed) PL (Completed) BE (Completed) ES (Completed) HU (Completed) SE (Completed) EE (Completed) IT (Completed) LT (Completed) SI (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-001201-24 Sponsor Protocol Number: KRT-232-104 Start Date*: 2019-12-02
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML).
    Medical condition: Relapsed or refractory AML, AML secondary to myeloproliferative neoplasms (MPN), and JAK2 mutationpositive AML.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) BE (Prematurely Ended) HU (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014456-29 Sponsor Protocol Number: Cord01 Start Date*: 2009-09-25
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: PHASE II STUDY OF LAPATINIB IN EGFR/HER2NEU POSITIVE ADVANCED CHORDOMA
    Medical condition: Advanced chordoma EGFR/Her2Neu positive
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039492 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003087-45 Sponsor Protocol Number: MYLOX-1 Start Date*: 2021-04-22
    Sponsor Name:Galecto Biotech AB
    Full Title: An open-label, phase IIa study of the safety, tolerability, pharmacokinetics and pharmacodynamics of oral GB2064 (a LOXL2 inhibitor) in participants with myelofibrosis (The MYLOX-1 study).
    Medical condition: Primary (PMF) or secondary (SMF) myelofibrosis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004916-51 Sponsor Protocol Number: SPI-ZEV-11-301 Start Date*: 2012-07-27
    Sponsor Name:Spectrum Pharmaceuticals, Inc.
    Full Title: A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (ibritumomab tiuxetan) versus Observation in Patients at Least 60 Years of Age with Newly Diagnosed Diffuse Large B-cell L...
    Medical condition: Diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) IT (Completed) ES (Prematurely Ended) BE (Completed) PT (Completed) NL (Completed) AT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-000104-15 Sponsor Protocol Number: CCS1477-02 Start Date*: 2021-07-29
    Sponsor Name:CellCentric Ltd
    Full Title: An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies.
    Medical condition: Acute Myeloid Leukaemia (AML)/high-risk Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Non-Hodgkin Lymphoma(NHL).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004689-11 Sponsor Protocol Number: MOR208C204 Start Date*: 2016-05-24
    Sponsor Name:MorphoSys AG
    Full Title: A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who ...
    Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012821 Diffuse large B-cell lymphoma recurrent PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) FI (Completed) PT (Completed) FR (Completed) AT (Completed) CZ (Completed) ES (Ongoing) RO (Ongoing) GB (GB - no longer in EU/EEA) HR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000383-18 Sponsor Protocol Number: LAL1913 Start Date*: 2014-05-20
    Sponsor Name:G.I.M.EM.A. Gruppo Italiano Malattie EMatologiche dell'Adulto
    Full Title: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented...
    Medical condition: National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia with Pegylated Asparaginase added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004427-38 Sponsor Protocol Number: 0001A3-300-GL Start Date*: 2009-01-28
    Sponsor Name:Antisoma Research Ltd.
    Full Title: Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML)
    Medical condition: secondary acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Ongoing) AT (Prematurely Ended) HU (Prematurely Ended) EE (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-010421-39 Sponsor Protocol Number: TRA112940 Start Date*: 2010-03-10
    Sponsor Name:GlaxoSmithKline
    Full Title: A longitudinal 2-year bone marrow study of eltrombopag olamine (SB-497115-GR) in previously treated adults, with chronic immune (idiopathic) thrombocytopenic purpura (ITP).
    Medical condition: Chronic Idiopathic Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    15.1 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FR (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001706-42 Sponsor Protocol Number: JCAR015-ALL-001 Start Date*: 2016-11-16
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Open-Label, Multiple Cohort, Single-Arm, Multi-Center Trial To Determine The Safety, Feasibility, And Efficacy Of JCAR015 In Adult Subjects With B-Cell Acute Lymphoblastic Leukemia
    Medical condition: B-cell Acute Lymphoblastic Leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003620-37 Sponsor Protocol Number: STH19580 Start Date*: 2019-10-31
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: NEPTUNE: Enhancement of immuNothEraPy combining avelumab and repeaT doses of radiUm-223 in ER+ve, HER2-ve metastatic breast caNcEr.
    Medical condition: ER+ve HER-ve breast cancer with bone metastases
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10006280 Breast neoplasm benign female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-004046-41 Sponsor Protocol Number: 273551 Start Date*: 2021-12-09
    Sponsor Name:University of Bergen,
    Full Title: A multicentre clinical trial; Alveolar bone augmentation using Mesenchymal Stem Cells and biphasic calcium phosphate granules prior to dental implants
    Medical condition: Patients in need of dental implant(s) in the upper and lower jaws with presence of bone defects with loss in vertical height and < than 4 mm in lateral width
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 09:33:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA